(HealthDay)— Though it began as a treatment for something else entirely, gastric bypass surgery—which involves shrinking the stomach as a way to lose weight—has proven to be the latest and possibly most effective treatment ...
Jan 4, 2013
1
0
A new therapeutic approach to diabetes that combines insulin and an inhibitor of the epidermal growth factor (EGF) betacellulin could limit the progression of diabetic macular edema (DME), Cleveland Clinic researcher Bela ...
Dec 17, 2012
0
0
Researchers at Karolinska Institutet in Sweden have managed to graft beta cells into the eyes of mice in order to study them in a living organism over a prolonged period of time. As a result, the group and a team of colleagues ...
Dec 10, 2012
0
0
(HealthDay)—A new, lab-created antibody that mimics the action of a naturally occurring molecule causes weight loss in monkeys, researchers report.
Nov 28, 2012
0
0
(HealthDay)—If the current trends in diabetes for young people stay the same, rates of type 2 diabetes will rise by 49 percent by 2050, and rates of type 1 diabetes will increase by 23 percent, according to new government ...
Nov 22, 2012
0
0
(HealthDay)—New guidelines meant to provide type 2 diabetes patients with truly individualized care have been issued by the American Diabetes Association and the European Association for the Study of Diabetes.
Oct 2, 2012
0
0
(Medical Xpress)—Using a new method, diabetes researchers at Lund University, Sweden, have been able to reveal more of the genetic complexity behind type 2 diabetes. The new research findings have been achieved as a result ...
Sep 4, 2012
0
1
Researchers at Mount Sinai School of Medicine have identified a common compound in the modern diet that could play a major role in the development of abdominal obesity, insulin resistance, and type 2 diabetes. The findings ...
Aug 20, 2012
3
0
A recent study led by Boston University School of Medicine (BUSM) demonstrates that the A2b-type adenosine receptor, A2bAR, plays a significant role in the regulation of high fat, high cholesterol diet-induced symptoms of ...
Jul 26, 2012
0
0
An extended trial of a drug for people with type 2 diabetes has confirmed that the oral DPP-4 inhibitor linagliptin is a safe and effective means of lowering glucose levels for up to 102 weeks, either on its own or in combination ...
Jul 23, 2012
0
0
